Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | PYGL | P06737 | 5/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14012583 | 1.00 | HPGD (0.53) | HPGDRAB9AABL1ALOX15MAPK1 | |
| SCHEMBL1110947 | 0.85 | MEN1 (0.53) | HPGDRAB9AABL1MAPK1KMT2A | |
| SCHEMBL28464953 | 0.84 | MAPT (0.52) | HPGDRAB9AMAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL3139349 | 0.84 | HPGD (0.47) | HPGDRAB9AABL1ALOX15MAPK1 | |
| SCHEMBL2708451 | 0.82 | SLC6A4 (0.51) | HPGDRAB9AABL1MAPK1KMT2A | |
| SCHEMBL30301996 | 0.82 | SLC6A4 (0.51) | HPGDRAB9AABL1MAPK1KMT2A | |
| SCHEMBL5787835 | 0.82 | HPGD (0.51) | HPGDRAB9AALOX15MAPK1KMT2A | |
| SCHEMBL14012584 | 0.81 | CES2 (0.61) | RAB9ASMN1; SMN2ALDH1A1SLC6A4SLC6A3 | |
| SCHEMBL2884923 | 0.81 | PDK2 (0.57) | HPGDRAB9AABL1KMT2ASMN1; SMN2 | |
| SCHEMBL608814 | 0.81 | ABL1 (0.68) | HPGDRAB9AABL1ALOX15MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119390577-A | Continuous preparation process of 2-chloro-4-fluoro-5-nitrobenzoic acid methyl ester | 苏利(宁夏)新材料科技有限公司 | 2025-02-07 | — | — | CN | claimed |
| EP-4271674-B9 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12570642-B2 | GLP-IR modulating compounds | GILEAD SCIENCES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4691554-A2 | GLP-1R MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4271674-B3 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4271672-B1 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250312352-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2025-10-09 | — | — | US | disclosed |
| EP-4520393-A2 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| CN-119546605-A | Protein degradation agent | 苏州开拓药业股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-4271674-B1 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-02-12 | — | — | EP | disclosed |
| US-6235900-B1 | Tricyclic pyridine N-oxides vasopressin agonists | AMERICAN HOME PRODUCTS CORPORATION | 2001-05-22 | — | — | US | disclosed |
| US-6194407-B1 | INCONTINENCE | AMERICAN HOME PRODUCTS CORPORATION | 2001-02-27 | — | — | US | disclosed |
| EP-1057818-A1 | PHENYLPIPERAZINE DERIVATIVES AS INTEGRIN ALPHAvBETA3 ANTAGONISTS | MEIJI SEIKA KAISHA LTD. (JP) | 2000-12-06 | — | — | EP | disclosed |
| WO-2000046224-A2 | TRICYCLIC PYRIDINE N-OXIDES VASOPRESSIN AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-08-10 | — | — | WO | disclosed |
| US-6090803-A | ANTIDIABETIC AGENTS; INCONTINENCE | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-07-18 | — | — | US | disclosed |
| EP-1000062-A1 | TRICYCLIC VASOPRESSIN AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-05-17 | — | — | EP | disclosed |
| EP-1000059-A1 | TRICYCLIC VASOPRESSIN AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999006403-A1 | TRICYCLIC VASOPRESSIN AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1999006409-A1 | TRICYCLIC VASOPRESSIN AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-02-11 | — | — | WO | disclosed |
| US-4670046-A | Tetrahydrophthalimide compounds, as post-emergence herbicides for use in soybean fields | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1987-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312352-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | HPGD 2944/4885RAB9A 478/4885ABL1 4100/4885 |
| US-12570642-B2 | GLP-IR modulating compounds | GLP1R, GIPR, GPR119 | HPGD 4632/4885RAB9A 244/4885ABL1 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.